Cart (0 Items)
Your cart is currently empty.
View ProductsDo you need to produce antibodies at gram-scale or beyond? Whether you are working in therapeutic, diagnostic, or veterinary antibody development, establishing a stable cell line is undoubtedly one of the most critical and costly steps. Yet, this step is crucial as it directly impacts the cost and quality of your biomolecule during large-scale manufacturing. At ProteoGenix, we understand these challenges, which is why we’ve left no stone unturned! Our stable cell line development process is meticulously designed to optimize both yield and final product quality, while minimizing development time and risk
No risk
Thanks to the numerous milestones included in our process, you will have the option to continue or stop your project based on clear data. In other words, you only proceed with the project if you are satisfied.
Future-focused
We offer the option to integrate a developability assessment of your sequence. We take into account various factors such as the presence of liability sequences, CDR analysis, solubility, and aggregation risks to help you avoid any future adjustments to your purification process.
High yield
Across more than a hundred projects, we have consistently achieved yields exceeding g/L levels.
Guaranteed yield
Minimizing risk also means ensuring visibility. From the start of the project, we assess its feasibility and provide you with a guaranteed yield estimate.
True proof of monoclonality, not just a probability
Thanks to the use of VIPSTM, we can provide you with real proof of monoclonality, which is crucial for confidently submitting your IND.
Proven and recognized expertise
With over 100 successful stable cell line projects, 1,500 proteins, and 5,000 antibodies produced, you can trust our expertise in biomolecule expression.
Custom process
You will communicate with a dedicated project manager who holds a PhD and will help you make the best choices for your project.
No royalties
ProteoGenix has selected royalty-free cell lines and owns its proprietary cell line, allowing you complete freedom for the future of your project.
Test the produced antibodies
To ensure confidence in your final product, we give you the opportunity to test the antibodies produced in your own laboratory!
Benefit from a FREE developability assessment
For any requests made before March 31. 2025,
receive a free developability assessment!
Step | Content | Timeline | Deliverables |
---|---|---|---|
Gene Synthesis and Cloning |
|
~1 week |
|
Transient Expression Evaluation |
|
~2 weeks |
|
Generation of Stable Pools |
|
~6 weeks |
|
Single Cell Clone Screening by VIPS™ |
|
~8-10 weeks |
|
RCB Preparation and QC |
|
~1 weeks |
|
RCB Stability Study |
|
~ 4-5 weeks |
|
Analytics |
|
~ 2-3 weeks |
|
At ProteoGenix, we make no compromises on the quality of our deliverables. We are committed to providing you with the best possible antibody from the start by offering a developability assessment aimed at minimizing or even eliminating the need for purification process adaptations.
As for the final deliverable, here are the various quality controls we offer (some are optional to help reduce the overall cost of the service, if necessary):
Ensuring monoclonality is critical in stable cell line development, as it guarantees high yields, reproducibility, and consistent quality in the final product. In the therapeutic field, demonstrating monoclonality holds even greater regulatory importance, as it’s a mandatory requirement for IND submissions.
At ProteoGenix, we provide true proof of monoclonality (not just a probability) through the cutting-edge VIPSTM technology. This advanced system integrates well-seeding, imaging, and AI-driven single-cell detection, ensuring that you receive definitive evidence of your cell line’s monoclonality. With this state-of-the-art solution, we not only confirm the true monoclonality of your stable cell line but also monitor its growth, allowing us to select the most promising clones for your project’s success.
Proprietary CHO-K1
CHO-STM
DG-44
HEK293 Variants (HEK293, 293F, 293E)
Customer-Specific Cell Lines
Single cell seeding / Monoclonality assurance
Affinity measurement
Affinity measurement
Thermal stability
Purity and aggregation
Antibody quality control by reducing and non-reducing conditions
We were recently approached by a biotech company aiming to produce its therapeutic antibody. Their initial transient production process delivered a yield of 6 mg/L with purity above 90%. Thanks to our stable cell line development service, we achieved a cell line capable of producing the antibody at 8.35 g/L with purity still exceeding 90%.
Curious about how we made this possible? Download our case study to find out!
5 questions to consider before choosing to insource your cell line development.
Ensuring monoclonality in therapeutic antibody production with VIPS technology
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.